DK0921810T3 - Reduktionen af alvorligheden af vært versus transplantat reaktionen (HVGR) ved at nedregulere autoimmuniteten - Google Patents

Reduktionen af alvorligheden af vært versus transplantat reaktionen (HVGR) ved at nedregulere autoimmuniteten

Info

Publication number
DK0921810T3
DK0921810T3 DK97940708T DK97940708T DK0921810T3 DK 0921810 T3 DK0921810 T3 DK 0921810T3 DK 97940708 T DK97940708 T DK 97940708T DK 97940708 T DK97940708 T DK 97940708T DK 0921810 T3 DK0921810 T3 DK 0921810T3
Authority
DK
Denmark
Prior art keywords
hvgr
severity
autoimmunity
reducing
downregulating
Prior art date
Application number
DK97940708T
Other languages
English (en)
Inventor
Irun R Cohen
Ohad Birk
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Application granted granted Critical
Publication of DK0921810T3 publication Critical patent/DK0921810T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Transplantation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
DK97940708T 1996-08-30 1997-09-02 Reduktionen af alvorligheden af vært versus transplantat reaktionen (HVGR) ved at nedregulere autoimmuniteten DK0921810T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/706,209 US5993803A (en) 1996-08-30 1996-08-30 Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
PCT/US1997/015294 WO1998008536A2 (en) 1996-08-30 1997-09-02 Method of reducing the severity of host vs. graft reaction by down-regulating hsp60 autoimmunity

Publications (1)

Publication Number Publication Date
DK0921810T3 true DK0921810T3 (da) 2003-07-28

Family

ID=24836651

Family Applications (1)

Application Number Title Priority Date Filing Date
DK97940708T DK0921810T3 (da) 1996-08-30 1997-09-02 Reduktionen af alvorligheden af vært versus transplantat reaktionen (HVGR) ved at nedregulere autoimmuniteten

Country Status (11)

Country Link
US (1) US5993803A (da)
EP (1) EP0921810B1 (da)
JP (1) JP4256474B2 (da)
AT (1) ATE237344T1 (da)
AU (1) AU722576B2 (da)
CA (1) CA2263816C (da)
DE (1) DE69721007T2 (da)
DK (1) DK0921810T3 (da)
ES (1) ES2198594T3 (da)
IL (2) IL128728A0 (da)
WO (1) WO1998008536A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9911772D0 (en) * 1999-05-21 1999-07-21 Semmelweis University Of Medic Diagnosis and treatment of atherosclerosis
IL150113A0 (en) * 1999-12-15 2002-12-01 Peptor Ltd Fragments and antagonists of heat shock protein 60
JP2004501061A (ja) * 1999-12-15 2004-01-15 ペプトル・リミテツド 熱ショックタンパク質６０のフラグメントおよびアンタゴニスト
US6812205B2 (en) * 2000-03-15 2004-11-02 The Brigham & Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
US6989146B2 (en) * 2000-08-09 2006-01-24 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
US7608683B2 (en) * 2000-08-09 2009-10-27 The Regents Of The University Of California Stress proteins and peptides and methods of use thereof
AU2001282475A1 (en) * 2000-08-25 2002-03-04 Yeda Research And Development Co. Ltd. Methods of treatment or prevention of autoimmune diseases with CpG-containing polynucleotide
AU2002220038A1 (en) 2000-11-01 2002-05-15 Alberto Martini Immunomodulatory peptides derived from heat shock proteins and uses thereof
WO2003063759A2 (en) * 2002-01-31 2003-08-07 Peptor Ltd. Hsp peptides and analogs for modulation of immune responses via antigen presenting cells
AU2003209623A1 (en) * 2002-02-19 2003-09-09 Yeda Research And Development Co. Ltd. Dual-effect ligands comprising anti-inflammatory hsp peptide epitopes for immunomodulation
WO2003096967A2 (en) 2002-05-21 2003-11-27 Yeda Research And Development Co. Ltd. Dna vaccines encoding heat shock proteins
US7494812B2 (en) * 2003-04-01 2009-02-24 University Of Southern California Generation of human regulatory T cells by bacterial toxins for the treatment of inflammatory disorders
WO2005048914A2 (en) * 2003-11-24 2005-06-02 Yeda Research & Development Co. Ltd. Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
AU2005207891B2 (en) * 2004-01-28 2010-04-01 Andromeda Biotech Ltd. Hsp therapy in conjunction with a low antigenicity diet
CU23504A1 (es) 2004-09-24 2010-04-13 Ct Ingenieria Genetica Biotech Péptidos y derivados tipo apl de la hsp60 y composiciones farmacéuticas
EP1835933A4 (en) * 2005-01-04 2015-01-07 Yeda Res & Dev HSP60, HSP60-PEPTIDES AND T-CELL VACCINES FOR IMMUNOMODULATION
WO2013128453A1 (en) 2012-03-01 2013-09-06 Yeda Research And Development Co. Ltd. Regeneration of islet beta cells by hsp60 derived peptides
WO2013128450A1 (en) 2012-03-01 2013-09-06 Yeda Research And Development Co. Ltd. Hsp60 derived peptides and peptide analogs for suppression and treatment of non-autoimmune diabetes

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92629A0 (en) * 1989-12-10 1990-08-31 Yeda Res & Dev Direct binding of t-cell epitopes to mhc gene products on intact living antigen presenting cells and the use thereof for identifying epitopes causing autoimmune diseases and pharmaceutical compositions for treating such diseases
EP0503055A1 (en) * 1990-09-06 1992-09-16 Rijksuniversiteit Utrecht Inhibitor of lymphocyte response and immune-related disease
IL114407A0 (en) * 1995-06-30 1995-10-31 Yeda Res & Dev Novel peptides and pharmaceutical compositions comprising them
IL114458A0 (en) * 1995-07-05 1995-11-27 Yeda Res & Dev Therapeutic preparations for treatment of T cell mediated diseases

Also Published As

Publication number Publication date
WO1998008536A3 (en) 1998-05-07
IL128728A (en) 2006-09-05
DE69721007T2 (de) 2004-02-12
AU722576B2 (en) 2000-08-10
US5993803A (en) 1999-11-30
JP4256474B2 (ja) 2009-04-22
WO1998008536A2 (en) 1998-03-05
ES2198594T3 (es) 2004-02-01
CA2263816A1 (en) 1998-03-05
IL128728A0 (en) 2000-01-31
ATE237344T1 (de) 2003-05-15
CA2263816C (en) 2008-12-30
EP0921810B1 (en) 2003-04-16
JP2001500488A (ja) 2001-01-16
AU4242697A (en) 1998-03-19
EP0921810A2 (en) 1999-06-16
DE69721007D1 (de) 2003-05-22

Similar Documents

Publication Publication Date Title
DK0921810T3 (da) Reduktionen af alvorligheden af vært versus transplantat reaktionen (HVGR) ved at nedregulere autoimmuniteten
CA2307874A1 (en) Structured voicemail messages
SE9103183L (sv) Virus-antikroppskomplex
AU1850597A (en) Combinations having immunosuppressive effects, containing cyclooxygenase-2-inhibitors and 5-lipoxygenase inhibitors
EP2295453A3 (en) An appetite-suppressing peptide, its compositions and use
GB2344886B (en) Selection of intracellular immunoglobulins
EP1052866A3 (en) High priority and/or emergency overload access control system
WO1995034320A3 (en) Methods for inhibiting antigen specific t cell responses
WO1997011888A3 (de) Magazin für die fixierung von kleinteilen
ATE363249T1 (de) Wirbelkäfigimplantat
AU4721696A (en) An osteogenic device and a method for preparing the device
EP1656892A3 (en) Expandable device comprising bistable unit cells
NZ312327A (en) Controlling hemipteran insect pests with bacillus thuringiensis
GB2363660A (en) A method and system for providing data to a user based on a user's query
EP1237073A3 (en) Method and system for creating and maintaining version-specific properties in a distributed environment
EP0855189A3 (en) Diffuser
GB2364616A (en) Electronic mail systems
EP1356818A3 (de) Medikament, insbesondere zur Modulation der Immunantwort bei der Bekämpfung von Viren, Tumoren, Bakterien und Parasiten
BG103677A (en) Solid mixtures based on sulphonylcarbamides and adjuvants
AR004753A1 (es) Una composicion enzimatica detergente.
AU3845095A (en) Childproof package for active substance patches
Clay The New Simonides and Homer's Hemitheoi
WO1999009167A8 (en) Porcine mhc class i genes and uses thereof
PT920502E (pt) Metodos e meios para modificacao da activacao do complemento
CA2262546A1 (en) Lo-cd2a antibody and uses thereof for inhibiting t cell activation and proliferation